| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Infinant Health | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $39.25M | Series A-2 | 5/21/2026 | $5.47M | $224.37M | $0.58 | Undisclosed Investors | ||||
 | Jnana Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $414.4M | Series C-2 | 11/15/2022 | $47M | $292.93M | $0.89 | Bain Capital, RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures, Pfizer Ventures | ||||
 | Korro Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $593.6M | Series B-2 | 1/5/2022 | $45.12M | $290.4M | $2.78 | Eventide Asset Management, Fidelity, Invus, Point72, Verition Fund Management, Monashee Investment Management, Sixty Degree Capital, Atlas Venture, NEA, Wu Capital, Qiming Venture Partners, Surveyor Capital, Cormorant Asset Management, MP Healthcare Venture Management, Alexandria Venture Investments | ||||
 | Mariana Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $250M | Series B | 9/7/2023 | $175M | $311.65M | $1.06 | Deep Track Capital, Forbion, Atlas Ventures, Access Biotechnology, RA Capital Management, Nextech Invest, Surveyor Capital, Eli Lilly and Company | ||||
 | NextPoint | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $196.84M | Series B | 7/30/2026 | $156.21M | $356.79M | $6.00 | Catalio Capital, MPM BioImpact, Leaps by Bayer, Sanofi Ventures, Invus, Sixty Degree Capital, Binney Street Capital, Gordon Freeman, Arkin Capital, WTT Investment, PagodaTree Partners | ||||
 | Proclara Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $112.79M | Series F | 11/7/2018 | $6.92M | $310.98M | $0.90 | Undisclosed Investors | ||||
 | Revolution Medicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | SafeTraces | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Sermonix Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Sonoma Biotherapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $365.1M | Series B-1 | 3/28/2023 | $147.78M | $732.39M | $2.96 | Ally Bridge Group, ArrowMark, Avidity Partners, Casdin Capital, Deep Track Capital, Fidelity Management, Frazier Healthcare Partners, GV, Janus Henderson Investors, Mirae Asset, NS Investment, Osage University Partners, Piper Heartland Healthcare Capital, Vertex Ventures HC, 8VC, ARCH Venture Partners, Alexandria Venture Investments, JDRF T1D Fund, LifeForce Capital, Lilly Asia Ventures Biosciences, Octagon Capital, Regeneron | ||||
 | Surrozen | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | SutroVax | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Synergys Biotherapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Tango Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $166.88M | Series B-1 | 8/17/2020 | $51.18M | $305.79M | $1.89 | Casdin Capital, Boxer Capital, Cormorant Asset Management, Gilead Sciences | ||||
 | Tenaya Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Tesis Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Theracos | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $135.86M | Series C | 9/20/2013 | $93.09M | $327.39M | $18.62 | Undisclosed Investors | ||||
 | Torque Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | TriSalus Life Sciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $198.81M | Series B-2 | 10/5/2022 | $15.32M | $375.88M | $0.35 | Undisclosed Investors | ||||
 | VisionGate | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | ARS Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $76.55M | Series D | 8/31/2021 | $55M | $310.11M | $5.89 | SR One, RA Capital Management, Deerfield | ||||
 | Brii BioSciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Cargo Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $507.54M | Series A-1 | 7/31/2023 | $86.04M | $302.29M | $13.57 | Ally Bridge Group, Cormorant, NexTech, Piper Heartland, Piper Sandler, RTW Sandler, RTW Investments, Third Rock Ventures, T. Rowe Price, Wellington, Xontongey, Janus Henderson, Emerson Collective, Red Tree Venture, Samsara BioCapital, Cormorant Capital | ||||
 | Clarus Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $109.16M | Series D | 6/12/2014 | $81.23M | $174.1M | $4.50 | Thomas McNerney & Partners, C-Bridge Capital, BVCF | ||||